Edition:
United States

Alnylam Pharmaceuticals Inc (ALNY.O)

ALNY.O on Nasdaq

39.47USD
10:07am EST
Change (% chg)

$0.51 (+1.31%)
Prev Close
$38.96
Open
$38.99
Day's High
$39.65
Day's Low
$38.77
Volume
86,563
Avg. Vol
1,541,237
52-wk High
$80.19
52-wk Low
$31.38

ALNY.O

Chart for ALNY.O

About

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its investigational RNAi... (more)

Overall

Beta: 2.68
Market Cap(Mil.): $3,343.31
Shares Outstanding(Mil.): 85.81
Dividend: --
Yield (%): --

Financials

  ALNY.O Industry Sector
P/E (TTM): -- 44.85 30.38
EPS (TTM): -4.54 -- --
ROI: -29.72 -1.38 14.86
ROE: -33.20 -1.07 16.28

BRIEF-The Medicines Company, Alnylam Pharmaceuticals present positive results from ORION-1 phase 2 study of Inclisiran

* The Medicines Company and Alnylam Pharmaceuticals present positive results from ORION-1 phase 2 study of Inclisiran (formerly PCSK9si)

Nov 15 2016

BRIEF-Alnylam pharmaceuticals announces Sanofi Genzyme opt-in decision

* Alnylam Pharmaceuticals announces Sanofi Genzyme opt-in decision for co-development and co-commercialization of fitusiran in hemophilia and rare bleeding disorders

Nov 14 2016

BRIEF-Alnylam Pharmaceuticals, Medicines Co announce publication of Phase 1 Clinical Data with Inclisiran

* Results from study showed doses 300 mg significantly reduced pcsk9 and ldl cholesterol for at least 6 months

Nov 13 2016

BRIEF-Alnylam Pharmaceuticals reports Q3 loss per share $1.21 including items

* Alnylam pharmaceuticals reports third quarter 2016 financial results and highlights recent period activity

Nov 02 2016

BRIEF-Alnylam Pharmaceuticals -Data monitoring committee recommends continuation of Apollo phase 3 clinical trial of Patisiran

* Data monitoring committee recommends continuation of Apollo phase 3 clinical trial of patisiran for hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN)

Oct 10 2016

Alnylam ends development of drug due to patient deaths in trial

Alnylam Pharmaceuticals Inc said on Wednesday it would halt development of an experimental therapy for a rare genetic condition that can cause heart failure, after a late-stage study showed that patients given the drug were more likely to die than patients treated with a placebo.

Oct 05 2016

BRIEF-Alnylam Pharma says discontinues revusiran development

* Decision to discontinue development of revusiran does not affect patisiran

Oct 05 2016

BRIEF-Alnylam presents clinical and non-clinical data

* Presents clinical and non clinical data demonstrating continued rnai platform optimization and leadership in the development of rna-based therapeutics at 12th annual meeting of the Oligonucleotide Therapeutics Society

Sep 28 2016

BRIEF-Alnylam expands and strengthens management team as it plans for commercialization

* Alnylam expands and strengthens management team as it plans for commercialization

Sep 19 2016

BRIEF-Alnylam completes enrollment in phase 3 study with revusiran

* Alnylam completes enrollment in endeavour phase 3 study with revusiran, an investigational rnai therapeutic for patients with hereditary attr amyloidosis with cardiomyopathy (hattr-cm)

Aug 08 2016

Earnings vs. Estimates